Pascolizumab (SB-240683) is a humanized anti-IL-4 monoclonal antibody. Pascolizumab has the potential for the research of asthma[1].
Pascolizumab 结合 IL-4 可抑制 IL-4 与 IL-4 受体的 α 链相互作用[1]。
Pascolizumab (0-10000 pM; 3 days) 显示出抗增殖活性，对 T 细胞和扁桃体 B 细胞的 IC50 值分别为 157、377 pM[1]。
Cell Proliferation Assay[1]
| Cell Line: | human or monkey T cells |
| Concentration: | 0-10000 pM |
| Incubation Time: | 3 days |
| Result: | Inhibited the response of human and monkey T cells to recombinant monkey IL-4 (2 ng/ml) with IC50 values of 268 pM and 587 pM, respectively. |
[1]. Hart TK, et al. Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma. Clin Exp Immunol. 2002 Oct;130(1):93-100.